Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers

被引：0
|
作者：
Charfi, Cyndia
Demeule, Michel
Currie, Jean-Christophe
Zgheib, Alain
Danalache, Bogdan Alexandru
Beliveau, Richard
Marsolais, Christian
Annabi, Borhane
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4493
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4493
引用
收藏
页数：2
相关论文
共 44 条
  • [21] Tucatinib potentiates the activity of the antibody-drug conjugate T-DM1 in preclinical models of HER2-positive breast cancer
    Kulukian, Anita
    Taylor, Janelle
    Jain, Nishi
    Olson, Devra
    Zaval, Margo
    Thurman, Robert
    Hengel, Shawna
    Farr, Lauren
    Pires, Thomas
    Peterson, Scott R.
    CANCER RESEARCH, 2021, 81 (04)
  • [22] Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer
    Lambert, John M.
    Chari, Ravi V. J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (16) : 6949 - 6964
  • [23] CLINICAL PHARMACOLOGY OF T-DM1: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) IN DEVELOPMENT FOR THE TREATMENT OF HER2-POSITIVE (HER2+) CANCER
    Girish, S.
    Gupta, M.
    Wang, B.
    Lu, D.
    Krop, I.
    Vogel, C.
    Burris, H.
    Yi, J.
    Saad, O.
    Tong, B.
    Klencke, B.
    Agresta, S.
    Chu, W.
    Joshi, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S12 - S12
  • [24] Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer
    Pegram, M.
    Hamilton, E.
    Tan, A. R.
    Storniolo, A. M.
    Elgeioushi, N.
    Marshall, S.
    Abdullah, S.
    Patel, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer
    Girish, Sandhya
    Gupta, Manish
    Wang, Bei
    Lu, Dan
    Krop, Ian E.
    Vogel, Charles L.
    Burris, Howard A., III
    LoRusso, Patricia M.
    Yi, Joo-Hee
    Saad, Ola
    Tong, Barbara
    Chu, Yu-Waye
    Holden, Scott
    Joshi, Amita
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1229 - 1240
  • [26] Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer br
    Zhang, Jian
    Ji, Dongmei
    Shen, Weina
    Xiao, Qin
    Gu, Yajia
    'Shaughnessy, Joyce
    Hu, Xichun
    CLINICAL CANCER RESEARCH, 2022, 28 (19) : 4212 - 4221
  • [27] Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers
    Musolino, Antonino
    Boggiani, Daniela
    Sikokis, Angelica
    Rimanti, Anita
    Pellegrino, Benedetta
    Vattiato, Rosa
    Sgargi, Paolo
    Falcini, Fabio
    Caminiti, Caterina
    Michiara, Maria
    Leonardi, Francesco
    CANCER TREATMENT REVIEWS, 2016, 43 : 1 - 7
  • [28] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
    Krop, Ian E.
    Beeram, Muralidhar
    Modi, Shanu
    Jones, Suzanne F.
    Holden, Scott N.
    Yu, Wei
    Girish, Sandhya
    Tibbitts, Jay
    Yi, Joo-Hee
    Sliwkowski, Mark X.
    Jacobson, Fred
    Lutzker, Stuart G.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2698 - 2704
  • [29] Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
    Chunze Li
    Bei Wang
    Dan Lu
    Jin Y. Jin
    Yuying Gao
    Kiyoshi Matsunaga
    Yuriko Igawa
    Ihsan Nijem
    Michael Lu
    Alexander Strasak
    Nataliya Chernyukhin
    Sandhya Girish
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 547 - 558
  • [30] Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
    Dan Lu
    Sandhya Girish
    Yuying Gao
    Bei Wang
    Joo-Hee Yi
    Ellie Guardino
    Meghna Samant
    Melody Cobleigh
    Mothaffar Rimawi
    Pierfranco Conte
    Jin Yan Jin
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 399 - 410
12345